Last reviewed · How we verify
NCT05320835: Oasis
A Setting Focus Overdose Prevention Intervention
NA trial testing HIV, HCV and overdose prevention in HIV Infections in 285 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Johns Hopkins Bloomberg School of Public Health |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 285 |
| Start date | 30 April 2022 |
| Primary completion | 1 May 2026 |
| Estimated completion | 30 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- HIV, HCV and overdose prevention
Conditions studied
- HIV Infections — all drugs for HIV Infections →
- HCV — all drugs for HCV →
- Drug Overdose — all drugs for Drug Overdose →
Sponsor
Johns Hopkins Bloomberg School of Public Health
Who can join
18 and older, any sex, with HIV Infections or HCV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05320835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other Johns Hopkins Bloomberg School of Public Health trials
Trials by the same sponsor.
- NCT07458230 — Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: · Phase 3 · not yet recruiting
- NCT07227558 — Improving Information Sharing Between Family Caregivers and Home Care Aides · NA · recruiting
- NCT07536126 — Testing Non-Nutrition Menu Labels on Food Selections · NA · not yet recruiting
- NCT06426004 — Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland · NA · not yet recruiting
- NCT07344142 — Improving Digital Wellbeing in Saudi Adolescents · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05320835 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins Bloomberg School of Public Health
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing